Chromocell Therapeutics has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications. Dr. Chandler is well suited to manage the program, with over 30 years of experience in managing ophthalmic drug development programs. He has a Ph.D in Epigenetics and had a post-doctoral position at the NIH studying molecular embryology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CHRO:
- Chromocell Therapeutics Appoints Experienced CEO Francis Knuettel II
- Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
- Chromocell Therapeutics names Frank Knuettel as permanent CEO
- Chromocell Therapeutics Showcases Pipeline at Sidoti Conference
- Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
Questions or Comments about the article? Write to editor@tipranks.com